SCHEMBL30717455

SCHEMBL30717455

CCN1CCN(c2nc3c(s2)CN(S(=O)(=O)Cc2ccc(F)cc2)CC3)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
GRM5 P41594 2/20 0.37
MAPK1 P28482 1/20 0.36
KDM2B Q8NHM5 2/20 0.36
SLC27A1 Q6PCB7 2/20 0.36
HTR6 P50406 1/20 0.35
RAD52 P43351 1/20 0.35
RECQL P46063 1/20 0.35
EGFR P00533 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30717609 0.86 NPC1 (0.44) NPC1RAB9AKMT2ASMN1; SMN2CYP1A2
SCHEMBL30717582 0.84 NPC1 (0.44) NPC1RAB9AKMT2ASMN1; SMN2GRM5
SCHEMBL31484857 0.79 DRD2 (0.45) NPC1RAB9AKMT2ADRD2HTR2A
SCHEMBL30717525 0.77 NPC1 (0.41) NPC1RAB9AKMT2ASMN1; SMN2POLB
SCHEMBL30717487 0.74 NPC1 (0.53) NPC1RAB9AKMT2APOLBGRM5
SCHEMBL30717667 0.72 GPR119 (0.41) NPC1RAB9AKMT2ACYP2D6
SCHEMBL12199721 0.70 RAB9A (0.53) NPC1RAB9AKMT2ASMN1; SMN2CYP1A2
SCHEMBL12680948 0.70 NPC1 (0.63) NPC1RAB9AKMT2ACYP2C19GRM5
SCHEMBL31484848 0.69 RORC (0.44) NPC1RAB9AKMT2ADRD2HTR6
SCHEMBL12199712 0.69 OGA (0.53) NPC1RAB9AKMT2ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572762-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 EP claimed
WO-2024038128-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LIMITED (GB) 2024-02-22 WO claimed
US-20250388604-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2025-12-25 US disclosed
EP-4572762-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 EP disclosed
WO-2024038128-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LIMITED (GB) 2024-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388604-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE7A, PDE4B NPC1 3054/4885RAB9A 701/4885KMT2A 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.